Novartis wants to eliminate price difference with the USA
Keystone-SDA
The Swiss pharmaceutical company Novartis wants to eliminate the price difference between medicines in the US and other industrialised countries. Group CEO Vasant Narasimhan believes that countries outside the US have a duty to contribute more to innovation.
“It is a fact that American patients pay for a large part of the innovations,” said Narasimhan in an interview with the Neue Zürcher Zeitung published on Saturday.
+Get the most important news from Switzerland in your inbox
The background to this is American President Donald Trump’s demand for price cuts. At the beginning of August, he gave Swiss companies such as Roche and Novartis, among others, a 60-day deadline to reduce their prices. This represents a challenge worth billions for the companies. Novartis is working with the government and trying to find “constructive solutions so that Americans have to pay less for their medicines”, said the CEO.
Swiss prices are ‘far too low’
When asked what this means for Switzerland, Narasimhan replied: “In Switzerland in particular, drug prices are far too low.” In comparison with other member countries of the OECD, the Organisation for Economic Co-operation and Development, they are at the lower end.
More
More
The high stakes fight over drug prices
In general, however, it is impossible to say how much more European countries would have to pay. “But even today, 30 to 40 per cent of cancer drugs, for example, are delayed or not launched on the European market at all,” said the Novartis CEO. This proportion will increase over time.
Complex US system
The Group is currently examining various mechanisms for possible price reductions. The US system is a complex construct with intermediaries and discounts. “Around half of our gross sales go to these middlemen,” said Narasimhan. The biggest opportunity in the US is to limit the influence of purchasing organisations.
More
More
How pharma became Switzerland’s Achilles heel in US trade talks
According to the CEO, Trump’s demand will not affect Novartis’ outlook in the medium term. As far as unforeseen events are concerned, he was optimistic: “No matter what happens, it should be possible to manage all changes under the current legal situation in the US,” he said.
Adapted from German by DeepL/ac
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
